Vaxcyte, Inc. (NASDAQ:PCVX) Stake Lessened by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 3.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,751 shares of the company’s stock after selling 211 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Vaxcyte were worth $434,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Mutual of America Capital Management LLC lifted its position in shares of Vaxcyte by 13.7% during the second quarter. Mutual of America Capital Management LLC now owns 50,813 shares of the company’s stock worth $3,837,000 after purchasing an additional 6,114 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of Vaxcyte by 12.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 47,961 shares of the company’s stock worth $3,622,000 after acquiring an additional 5,268 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Vaxcyte in the 2nd quarter valued at approximately $277,000. Nicholas Investment Partners LP raised its position in shares of Vaxcyte by 1.9% during the 2nd quarter. Nicholas Investment Partners LP now owns 87,230 shares of the company’s stock valued at $6,587,000 after acquiring an additional 1,586 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in Vaxcyte by 14.3% during the second quarter. American Century Companies Inc. now owns 527,594 shares of the company’s stock worth $39,839,000 after purchasing an additional 65,870 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on PCVX. Jefferies Financial Group increased their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Needham & Company LLC raised their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th. BTIG Research increased their price target on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $147.50.

Insider Buying and Selling

In related news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $75.64, for a total value of $1,134,600.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares in the company, valued at approximately $36,223,088.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $81.17, for a total transaction of $649,360.00. Following the sale, the chief financial officer now owns 96,720 shares in the company, valued at $7,850,762.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $75.64, for a total transaction of $1,134,600.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $36,223,088.32. The disclosure for this sale can be found here. Insiders sold 85,283 shares of company stock valued at $7,271,218 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Trading Down 0.2 %

Shares of NASDAQ PCVX opened at $116.54 on Thursday. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $119.50. The company has a market cap of $12.68 billion, a PE ratio of -27.23 and a beta of 0.97. The stock has a 50 day simple moving average of $87.76 and a 200-day simple moving average of $75.76.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same period last year, the business posted ($0.70) EPS. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.